Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
ESMO Open
|
April 10, 2026
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial
I Dirven, C Bertels, Y Moreels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
A H Boekhout, A Rogiers, K Jozwiak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
L Kandolf Sekulovic, J Guo, S Agarwala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
P Grover, S N Lo, I Li, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
ESMO Open
|
April 10, 2026
Efficacy and safety of regorafenib in patients with advanced pretreated melanoma: results of the RegoMel phase II clinical trial
I Dirven, C Bertels, Y Moreels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 30, 2019
Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma
Y J L Jansen, E A Rozeman, R Mason, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
A H Boekhout, A Rogiers, K Jozwiak, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee
O Michielin, A van Akkooi, P Lorigan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 9, 2020
ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee
U Keilholz, P A Ascierto, R Dummer, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 8, 2017
More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments
L Kandolf Sekulovic, K Peris, A Hauschild, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 3, 2018
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries
L Kandolf Sekulovic, J Guo, S Agarwala, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 2, 2021
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma
C N Owen, X Bai, T Quah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2025
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma
P Grover, S N Lo, I Li, et al.
Page
of 5